Biro Pengawalan Farmaseutikal Kebangsaan
National Pharmaceutical Control Bureau
KEMENTERIAN KESIHATAN MALAYSIA
MINISTRY OF HEALTH MALAYSIA

Ruj. Kami : (16) dlm. BPFK/PPP/01/03 Jld. 3
Tarikh : 04 AUG 2014

SEMUA PEMEGANG PENDAFTARAN

SEMUA PERSATUAN BERKENAAN
(SEPERTI DI SENARAI EDARAN)

Tuan/ Puan,

PEKELILING TENTANG LANGKAH-LANGKAH PENGURANGAN RISIKO BAGI PRODUK YANG MENGANDUNGI STRONTIUM RANELATE SUSULAN RISIKO KESAN ADVERS KARDIOVASKULAR

Saya dengan segala hormatnya merujuk kepada perkara di atas.

1. Pihak Berkuasa Kawalan Dadah (PBKD) dalam mesyuarat kali ke **277** pada **7 Julai 2014** telah bersetuju dengan langkah-langkah pengurangan risiko bagi produk yang mengandungi strontium ranelate susulan risiko kesan advers kardiovaskular.

2. Oleh itu arahan – arahan berikut perlu dipatuhi untuk semua produk yang mengandungi strontium ranelate:-

2.1 **Mengemaskini sisip bungkusan** produk yang mengandungi strontium ranelate dengan mengehadkan penggunaan dan memperkukuhkan amaran berkaitan dengan risiko kesan advers kardiovaskular:

i) ***Black box warning*** dimuatkan pada bahagian pertama sisip bungkusan:

> *[Brand Name]* should only be used for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance.
> *[Brand Name]* is contraindicated in patients with:
> - established, current or past history of ischaemic heart disease; peripheral arterial disease and/or cerebrovascular disease;
> - uncontrolled hypertension;
> - current or previous venous thromboembolic events (VTE);
> - temporary or permanent immobilisation.

Jalan Universiti. P. O. Box 319, 46730 Petaling Jaya, Selangor, Malaysia
Tel. : + 603 7883 5400 Fax : + 603 7956 2924 / 7958 1312
http : //www.bpfk.gov.my

ii) Pada bahagian ***Indication***

- *Treatment of **severe/established** osteoporosis in postmenopausal women **at high risk of fracture** to reduce the risk of vertebral and hip fractures*
- *Treatment of **severe/established** osteoporosis in men at increased risk of fracture*

[Brand Name] should only be used for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance.

iii) Pada bahagian ***Contraindications***

- ***Established, current or past history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease***
- ***Uncontrolled hypertension***

iv) Pada bahagian ***Special warnings and precautions for use***:

Cardiac ischaemic events

In pooled randomised placebo-controlled studies of post-menopausal osteoporotic patients, a significant increase in myocardial infarction has been observed in strontium ranelate treated patients compared to placebo.

Before starting treatment, patients should be evaluated with respect to cardiovascular risk.

Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with strontium ranelate after careful consideration.

During [BRAND NAME] treatment, these cardiovascular risks should be monitored on a regular basis generally every 6 to 12 months.

Treatment should be stopped if the patient develops ischaemic heart disease, peripheral arterial disease, cerebrovascular disease or if hypertension is uncontrolled.

v) Pada bahagian ***Undesirable effects***:

SOC Cardiac disorders:
- ***Common: Myocardial infarction***

Myocardial infarction

In pooled randomised placebo-controlled studies of post-menopausal osteoporotic patients, a significant increase of myocardial infarction has been observed in strontium ranelate treated patients as compared to placebo (1.7% versus 1.1%), with a relative risk of 1.6 (95% CI = [1.07; 2.38]).

2.2 Pemegang pendaftaran produk perlu mengedarkan *Direct Healthcare Professional Communication (DHPC)* berserta ***prescribing checklist*** dan seterusnya mendapat **tandatangan doktor sebagai pengesahan penerimaan DHPC** tersebut.

3. Tarikh pelaksanaan keperluan mengemaskini maklumat berkenaan pada sisip bungkusan semua produk yang mengandungi strontium ranelate bagi:

(a) Permohonan baru dan produk yang sedang dalam proses penilaian : **01 Ogos 2014**

(b) Produk berdaftar : **dalam tempoh Enam bulan mulai 01 Ogos 2014**

4. Permohonan pindaan pada sisip bungkusan perlu dikemukakan sebagai permohonan variasi.

5. Tarikh kuat kuasa arahan ini ialah mulai **01 Ogos 2014.**

Sekian, terima kasih.

"BERKHIDMAT UNTUK NEGARA"

Saya yang menurut perintah,

TAN ANN LING
Pengarah Regulatori Farmasi
Biro Pengawalan Farmaseutikal Kebangsaan
Kementerian Kesihatan Malaysia

rt/nb/ppp/bpfk/220714

s.k. 1. Pengarah Kanan Perkhidmatan Farmasi
Bahagian Perkhidmatan Farmasi
Kementerian Kesihatan Malaysia.

2. Pengarah Penguatkuasa Farmasi
Bahagian Perkhidmatan Farmasi
Kementerian Kesihatan Malaysia.

3. Pengarah Amalan dan Perkembangan Farmasi
Bahagian Perkhidmatan Farmasi
Kementerian Kesihatan Malaysia.